Company Insights

BTMD supplier relationships

Explore interactive graphBrowse insights index
BTMD supplier relationship map

Biote Corp (BTMD): supplier relationships that drive pellet-and-supplement economics

Biote Corp operates a vertically oriented provider model to the hormone-replacement and practitioner-supplied supplement market: the company sells Biote-branded dietary supplements and bioidentical hormone pellets to partnered clinics, sources manufacturing from FDA-registered 503B outsourcing facilities and multiple U.S.-based suppliers, and monetizes through product margins, insertion kits and logistics pass-throughs. Revenue is product-led and supplier-dependent—the firm purchases finished goods and pellets, warehouses and ships via third-party logistics partners, and captures value in branded product sales and clinician distribution. Learn more about supplier risk and opportunities at https://nullexposure.com/.

How suppliers plug into Biote’s economics

Biote’s gross profit margin and operating leverage are underpinned by two supplier cohorts: manufacturers of hormone pellets and third-party packagers/3PLs for supplements. The pellets—sourced largely from a company-controlled 503B compounding pharmacy and supplemented by external 503B outsourcing facilities—are central to practitioner demand and constitute a pass-through cost in product revenue. Separately, 24 branded supplements are manufactured to Biote’s specifications by 11 U.S.-based suppliers, with warehousing and fulfillment outsourced to a third-party logistics provider. The company’s FY2025 revenue of $192.2 million and gross profit of $137.4 million establish the supplier network as the operational spine for recurring product sales.

Supplier relationships — what investors need to know

AnazaoHealth Corp.

AnazaoHealth is contracted as an FDA-registered 503B outsourcing facility that supplies hormone pellets to Biote to meet demand beyond the company’s primary compounding pharmacy. Bloomberg Law reported on Biote’s supply disclosures and noted AnazaoHealth’s role in FY2019 as an outsourcing facility supplier. (Bloomberg Law, March 2026)

Carie Boyd’s Prescription Shop

Carie Boyd’s Prescription Shop is identified as an outsourced 503B facility used by Biote for custom-made hormone pellets; Bloomberg Law’s reporting linked the entity to pellet production and distribution that were marketed to physicians and hospitals in FY2019. (Bloomberg Law, March 2026)

Asteria

Asteria operates as Biote’s primary pellet production facility and has secured state licenses to supply a majority share of practitioner pellet orders, supplying more than 50% of pellets at the time described in the Q3 2025 earnings transcript. (Q3 2025 earnings call transcript, InsiderMonkey)

Jefferies

Jefferies acted as financial and capital markets advisor to Biote in the company’s public listing process, indicating an investment banking advisor relationship during the FY2022 transaction period. (stocktitan.net report on Biote’s public debut, FY2022)

Cooley LLP

Cooley LLP served as legal advisor to Biote around the company’s public listing events in FY2022, representing the legal advisory relationship that supported capital markets activity. (stocktitan.net report on Biote’s public debut, FY2022)

AdvisIRy Partners

AdvisIRy Partners is the named investor relations contact for Biote in FY2026 corporate disclosures and investor communications, reflecting an ongoing IR services relationship. (stocktitan.net scheduling announcement, FY2026)

What the relationship constraints reveal about operating posture

The company-provided relationship constraints paint a clear operational profile rather than isolated metrics.

  • Contracting posture: Biote uses formal agreements with FDA-registered 503B outsourcing facilities and multiple manufacturing suppliers, indicating a contractual reliance on regulated third-party manufacturers for critical product components (pellets) and supplier agreements for branded supplements. The firm also contracts third-party warehousing, co-packing and logistics services for distribution.
  • Concentration and geography: Supplier sourcing is U.S.-centric—Biote reports 11 U.S.-based supplement manufacturers and sells 24 custom-branded supplements produced domestically—reducing cross-border supply chain complexity but concentrating regulatory and operational risk within U.S. channels.
  • Criticality: Pellets are critical to Biote’s practitioner value proposition; the company notes a majority are produced by its 503B compounding pharmacy, with AnazaoHealth and Carie Boyd as named outsourcing backups, signaling single-product criticality supported by a small set of regulated manufacturers.
  • Maturity and stage: Relationships are active and operational, not pilot-stage; the company references ongoing agreements with named 503B facilities and established 3PL arrangements.
  • Financial exposure and spend: Purchases from a founder-affiliated vendor totaled $0.7 million in FY2024 and $1.4 million in FY2023, placing some supplier spend in the mid-single-digit millions range and individual vendor exposure at an immaterial accounts-payable level ($0.1 million payable at year-end 2024), but notable enough to warrant governance scrutiny given the related-party element.

Risk, concentration and governance takeaways

  • Supplier concentration on regulated pellet manufacturing is a material operational dependency. Biote’s practitioner proposition requires dependable pellet supply; disruptions at the 503B facilities would directly reduce revenue flow from pellet-based services.
  • Domestic sourcing reduces geopolitical risk but increases regulatory risk concentration. Compliance and FDA scrutiny of outsourcing facilities are front-and-center risks for operators and investors.
  • Founder-affiliated vendor purchases warrant governance review despite immaterial payables. The founder-related vendor delivered $0.7m of inventory in FY2024, a non-trivial procurement line given the company’s supplier base.
  • Advisors and IR partners signal capital markets maturity. Jefferies and Cooley’s roles in FY2022 reflect a completed public listing and established capital markets relationships; AdvisIRy Partners provides ongoing investor communications support in FY2026.

Practical investor actions

  • Monitor 503B supplier disclosures and FDA inspection outcomes because pellet production is core to revenue; any regulatory action will have immediate operational impact.

  • Request granular spend and concentration schedules for the top 10 suppliers and the founder-affiliated vendor to assess procurement governance and replacement risk.

  • Validate logistics resilience by reviewing 3PL contracts, fulfillment KPIs and contingency plans for disruptions in warehousing or co-packing.

  • Learn more about supplier exposure analysis and vendor risk scoring at https://nullexposure.com/.

Biote’s model is product-centric with suppliers embedded in the revenue engine: regulated manufacturing partners for pellets and a diversified roster of U.S. supplement manufacturers and 3PLs for distribution. For investors and operators, the decisive variables are regulatory health of 503B partners, procurement governance around related-party vendors, and operational resilience of fulfillment partners. For a focused supplier-risk audit and benchmarking against peers, visit https://nullexposure.com/.